Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Spondyloarthritis
What is your experience with using oral roflumilast for psoriatic arthritis?
Related Questions
Would you transition a patient with axial spondyloarthritis to a biologic if their axial symptoms were controlled with an NSAID, but they also required a PPI to control dyspepsia/GERD caused by the NSAID?
Would you switch to bimekizumab if a patient with psoriatic arthritis who is already on an IL-17 inhibitor has breakthrough skin or joint disease?
What is your approach to choosing a particular advanced therapy based on patient or disease factors when initiating treatment for moderate-severe IBD?
What circumstances would drive you to consider using an oral IL-23 inhibitor over parenteral options for the management of psoriasis and/or psoriatic arthritis?
How would you manage active severe psoriasis in a patient planning pregnancy, who also has psoriatic arthritis with well-controlled joint symptoms on certolizumab pegol (anti-TNF therapy)?
Would you escalate treatment for a patient with Crohn disease with changes suggestive of chronic sacroiliitis on MRI but without bone marrow edema or effusion that suggests active inflammation?
What is your approach to differentiating tender spots (as in fibromyalgia) and enthesitis (as in axSpA)?
In a patient with isolated HLA B27+ anterior uveitis, how long would you continue immunosuppressive therapy?
Would you choose bimekizumab over other IL-17 inhibitors in patients with increased levels of disease related pain and poor functional status?
Where do you anticipate using bimekizumab in your sequence of treatment options for a patient with psoriatic arthritis?
